Xenon Pharmaceuticals (XENE) to Release Earnings on Monday

Key Points

• Xenon Pharmaceuticals is expected to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($1.03) per share.
• In its last earnings report, the company beat estimates with a loss of ($0.83) per share and reported revenue of $7.50 million, significantly higher than the forecast of $1.64 million.
• Xenon Pharmaceuticals currently has a market cap of $2.68 billion and an average analyst rating of "Moderate Buy" with a consensus price target of $54.82.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Monday, August 11th. Analysts expect Xenon Pharmaceuticals to post earnings of ($1.03) per share for the quarter.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to analysts' expectations of $1.64 million. During the same period in the prior year, the firm posted ($0.62) earnings per share. On average, analysts expect Xenon Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Xenon Pharmaceuticals Stock Down 0.6%

NASDAQ:XENE traded down $0.20 during mid-day trading on Friday, reaching $33.43. The company's stock had a trading volume of 865,066 shares, compared to its average volume of 920,234. The firm has a market capitalization of $2.57 billion, a PE ratio of -10.35 and a beta of 1.16. The stock has a fifty day moving average of $31.98 and a 200-day moving average of $34.13. Xenon Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $46.00.

Analysts Set New Price Targets

XENE has been the topic of several recent analyst reports. William Blair restated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. The Goldman Sachs Group cut their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Wall Street Zen downgraded shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Needham & Company LLC cut their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, Royal Bank Of Canada cut their price target on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $54.82.

Institutional Investors Weigh In On Xenon Pharmaceuticals

An institutional investor recently raised its position in Xenon Pharmaceuticals stock. Goldman Sachs Group Inc. grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 442,732 shares of the biopharmaceutical company's stock after purchasing an additional 32,486 shares during the period. Goldman Sachs Group Inc. owned approximately 0.58% of Xenon Pharmaceuticals worth $14,854,000 at the end of the most recent reporting period. Institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.